HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan’s New Rx-To-OTC Procedure Exacerbating Switch Blockage Says JSMI

Executive Summary

Japan's new Rx-to-OTC switch procedure has exacerbated a "switch lag" compared with developed countries, says Japan Self-Medication Industry senior adviser Toshi Tominaga in an exclusive interview with HBW Insight. Tominaga proposes improvements such as self-care education for consumers and drug usage advice included by firms in switch applications to help balance the risk-benefit decisions of expert judges. 

You may also be interested in...



Asia’s OTC Market Stunted By Regulatory Disharmony

HBW Insight Exclusive: A lack of regulatory harmonization, especially with regards to Rx-to-OTC switch, is holding the Asia-Pacific OTC market back, according to APSMI secretary general, Toshi Tominaga.

GSK Launches OTC Fluticasone In Japan Following Switch

GSK has launched Flunase in Japan following the switch of fluticasone propionate. JSMI’s Toshi Tominaga gives his assessment of the product’s prospects as an OTC drug.

Post-Switch Market Exclusivity Benefits Everyone, Insists Global Switch Expert

Three- to five-year market exclusivity periods for switched products would not only incentivize consumer healthcare firms but also enable pre- and post-switch data to be generated more easily, thus improving the quality of switch applications, explains global switch expert Dr Natalie Gauld in the final part of our exclusive interview. 

Related Content

Topics

UsernamePublicRestriction

Register

LL1122113

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel